---
id: ats-pulmonary-hypertension-2024
title: "ATS/CHEST 2024 Clinical Practice Guideline: Pulmonary Arterial Hypertension"
short_title: "ATS Pulmonary HTN 2024"

organization: American Thoracic Society
collaborators:
  - American College of Chest Physicians
country: US
url: https://www.thoracic.org/statements/
doi: null
pmid: null
open_access: true

specialty: pulmonology
guideline_type: clinical-practice
evidence_system: ATS GRADE
conditions:
  - pulmonary arterial hypertension
  - PAH
  - pulmonary hypertension
tags:
  - PDE-5 inhibitors
  - endothelin receptor antagonists
  - prostacyclins
  - right heart catheterization
  - combination therapy

publication_date: 2024-06-01
previous_version_date: 2022-08-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-26
---

## Scope
2024 ATS/CHEST clinical practice guideline update on the diagnosis and treatment of pulmonary arterial hypertension (PAH, WHO Group 1).

## Key Recommendations

### Diagnosis
- **Suspect PAH**: Unexplained dyspnea, exercise intolerance, signs of right heart failure.
- **Echocardiography**: Initial screening; estimate RVSP, RV function.
- **Right Heart Catheterization (RHC)**: Required for diagnosis.
  - Mean PAP ≥20 mmHg, PAWP ≤15 mmHg, PVR ≥3 Wood units.
- Rule out other causes: Left heart disease, lung disease, CTEPH.

### Risk Stratification
- Use multiparameter risk assessment: WHO functional class, 6MWD, BNP/NT-proBNP, RV function, hemodynamics.
- Classify as low, intermediate, or high risk to guide therapy.

### Treatment

#### General Measures
- Diuretics for fluid management.
- Oxygen if hypoxic.
- Anticoagulation (consider in IPAH, CTEPH).
- Avoid pregnancy.

#### PAH-Specific Therapy

##### Low-to-Intermediate Risk (Initial)
- **Combination Therapy**: Upfront dual oral therapy is standard.
  - **Ambrisentan or Macitentan (ERA)** + **Tadalafil or Sildenafil (PDE-5i)**.

##### High-Risk (Severe Symptoms or Hemodynamics)
- **Upfront Triple Therapy**: ERA + PDE-5i + Parenteral Prostacyclin (IV epoprostenol or treprostinil).
- Or ERA + Riociguat (sGC stimulator) + Prostacyclin.

##### Prostacyclins
- **IV Epoprostenol, IV/SC Treprostinil**: For high-risk or refractory patients.
- **Inhaled Treprostinil/Iloprost, Oral Selexipag**: Additional options.

### Follow-Up
- Regular reassessment of risk (every 3-6 months).
- Adjust therapy if not meeting treatment goals.

### Transplantation
- Refer for lung transplant evaluation in patients with progressive disease despite optimal medical therapy.
